drugset

drugset / Trial / NCT07321951

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

NCT07321951 ↗

Phase 2 Active not recruiting 201 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.

Timeline

Start: 2026-01-09
Primary completion: 2027-06
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1819	Monoclonal antibody	—	—

Indications